B. Riley FBR analyst Andrew D'Silva says his channel checks related to Iluvien over the past two weeks, including calls with some of Alimera Sciences' new sales reps and retinal specialists, show a "substantial" quarter-over-quarter recovery. The due diligence makes the analyst "incrementally more confident" on Alimera being able to post a "significant recovery" in Q3 following the shortfall in Q2. D'Silva, who views the Q3 consensus revenue estimate as beatable, continues to believe Alimera is "significantly undervalued." He reiterates a Buy rating on the shares with a $2.00 price target.